How is Selpercatinib Administered? Understanding Usage for RET-Altered Cancers
•
4 min read
In clinical trials, selpercatinib has demonstrated objective response rates as high as 85% in patients with certain RET fusion-positive cancers. This guide explains how is selpercatinib administered to achieve these results, focusing on proper usage, patient considerations, and managing potential side effects.
